Patent ID: 6846836

Claim:
A method of treating a mitochondrial F 1 F 0 ATP hydrolase associated disorder selected from myocardial infarction; ventricular hypertrophy; coronary artery disease; non-Q wave MI; congestive heart failure; cardiac arrhythmias; unstable angina; chronic stable angina; Prinzmetal's angina; high blood pressure; intermittent claudication; peripheral occlusive arterial disease; thrombotic or thromboembolic symptoms of thromboembolic stroke; venous thrombosis; arterial thrombosis; cerebral thrombosis; pulmonary embolism; cerebral embolism; thrombophilia; disseminated intravascular coagulation; restenosis; atrial fibrillation; ventricular enlargement; atherosclerotic vascular disease; atherosclerotic plague rupture; atherosclerotic plague formation; transplant atherosclerosis; vascular remodeling atherosclerosis; cancers having tumor cells that do not exhibit the Warburg effect; inflammation; systematic infection; thromboembolic complications of surgery, artificial surfaces, interventional cardiology, immobility, medication, pregnancy and/or fetal loss; and diabetic complications comprising retinopathy, nephropathy and neuropathy in a mammal comprising administering to the patient in need of such treatment an effective amount of at least one compound having the formula (I): their enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein: X is selected from O or S; A is selected from hydrogen, alkyl, substituted alkyl, cycloalkyl, heterocycle, aryl, and heteroaryl; n and mare 0, 1, or 2 R 1 through R 5 are independently selected from hydrogen, halogen, NO 2 , CN, C 1-8 alkyl, substituted C 1-8 alkyl, C 3-8 cycloalkyl, aryl, heterocyclo, heteroaryl, OR 9 , SR 9 , COR 11 , CO 2 R 11 , CONR 9 R 10 or NR 9 R 10 ; R 6 and R 7 are independently hydrogen, alkyl or substituted alkyl; R 8 is hydrogen; C 1-8 alkyl, substituted C 1-8 alkyl, aryl, heterocyclo or heteroaryl; Z is hydrogen, alkyl, substituted alkyl, cycloalkyl, aryl, heterocyclo, heteroaryl, COR 11 , CO 2 R 11 , SO 2 R 11 , S(O)R 11 or CONR 9 R 10 ; R 9 and R 10 are independently hydrogen, C 1-8 alkyl, substituted C 1-8 alkyl, C 3-10 cycloalkyl, aryl, heterocyclo, heteroaryl, COR 13 , SO 2 R 13 or S(O)R 13 ; and R 11 , R 12 and R 13 are independently hydrogen, C 1-8 alkyl, substituted C 1-8 alkyl, C 3-10 cycloalkyl, aryl, heterocyclo or heteroaryl; wherein each occurrence of R 9 -R 13 is chosen independently.